BMY Stock Gets Increased EPS Estimate from Zacks Research

Bristol Myers Squibb Company (NYSE:BMY) – Research analysts at Zacks Research raised their Q3 2027 EPS estimates for Bristol Myers Squibb in a research note issued on Thursday, September 24th. Zacks Research analyst Team now anticipates that the biopharmaceutical company will post earnings per share of $1.56 for the quarter, up from their previous estimate of $1.55. The consensus estimate for Bristol Myers Squibb’s current full-year earnings is $6.95 per share. Zacks Research also issued estimates for Bristol Myers Squibb’s FY2027 earnings at $6.24 EPS, Q1 2028 earnings at $1.48 EPS, Q2 2028 earnings at $1.38 EPS and FY2028 earnings at $5.23 EPS.

Other equities research analysts have also recently issued research reports about the company. Jefferies Financial Group cut Bristol Myers Squibb from a “buy” rating to a “hold” rating in a report on Wednesday, August 5th. BMO Capital Markets reiterated a “market perform” rating on shares of Bristol Myers Squibb in a research report on Monday, July 27th. Piper Sandler reissued an “overweight” rating and issued a $82.00 price objective (up from $75.00) on shares of Bristol Myers Squibb in a research note on Wednesday, September 16th. JPMorgan Chase & Co. upped their price objective on Bristol Myers Squibb from $67.00 to $73.00 and gave the company an “overweight” rating in a report on Friday, July 31st. Finally, Citigroup reaffirmed a “neutral” rating and set a $70.00 target price (up from $66.00) on shares of Bristol Myers Squibb in a research note on Monday, August 3rd. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, ten have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $67.06.

Bristol Myers Squibb Trading Up 0.6%

Shares of NYSE:BMY opened at $61.54 on Friday. Bristol Myers Squibb has a twelve month low of $42.52 and a twelve month high of $68.64. The company has a current ratio of 1.53, a quick ratio of 1.38 and a debt-to-equity ratio of 1.89. The firm has a market cap of $125.71 billion, a P/E ratio of 13.56, a P/E/G ratio of 0.30 and a beta of 0.23. The company has a 50 day moving average of $64.44 and a 200-day moving average of $60.15.

Bristol Myers Squibb (NYSE:BMY) last posted its earnings results on Thursday, July 30th. The biopharmaceutical company reported $2.04 EPS for the quarter, beating the consensus estimate of $1.60 by $0.44. The firm had revenue of $12.97 billion for the quarter, compared to analysts’ expectations of $11.74 billion. Bristol Myers Squibb had a return on equity of 66.90% and a net margin of 18.87%.The firm’s revenue was up 5.7% compared to the same quarter last year. During the same period last year, the firm earned $1.46 EPS. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS.

Bristol Myers Squibb Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, November 2nd. Stockholders of record on Friday, October 2nd will be given a dividend of $0.63 per share. This represents a $2.52 dividend on an annualized basis and a dividend yield of 4.1%. The ex-dividend date is Friday, October 2nd. Bristol Myers Squibb’s dividend payout ratio is 55.51%.

Insider Buying and Selling at Bristol Myers Squibb

In related news, SVP Phil M. Holzer sold 500 shares of Bristol Myers Squibb stock in a transaction on Tuesday, August 25th. The stock was sold at an average price of $67.50, for a total value of $33,750.00. Following the transaction, the senior vice president directly owned 16,862 shares in the company, valued at $1,138,185. The trade was a 2.88% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. 0.05% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. QRG Capital Management Inc. grew its position in Bristol Myers Squibb by 4.2% during the 2nd quarter. QRG Capital Management Inc. now owns 370,802 shares of the biopharmaceutical company’s stock worth $21,955,000 after purchasing an additional 14,906 shares in the last quarter. Envestnet Portfolio Solutions Inc. lifted its stake in Bristol Myers Squibb by 28.2% in the 2nd quarter. Envestnet Portfolio Solutions Inc. now owns 110,400 shares of the biopharmaceutical company’s stock worth $6,930,000 after acquiring an additional 24,285 shares in the last quarter. Envestnet Asset Management Inc. boosted its position in Bristol Myers Squibb by 17.4% during the 2nd quarter. Envestnet Asset Management Inc. now owns 2,142,754 shares of the biopharmaceutical company’s stock worth $123,465,000 after acquiring an additional 317,360 shares during the period. State Street Corp grew its stake in Bristol Myers Squibb by 7.3% during the 2nd quarter. State Street Corp now owns 105,757,638 shares of the biopharmaceutical company’s stock valued at $6,093,755,000 after acquiring an additional 7,192,724 shares in the last quarter. Finally, Security National Bank of SO Dak acquired a new position in shares of Bristol Myers Squibb in the 2nd quarter valued at about $59,000. 76.41% of the stock is owned by hedge funds and other institutional investors.

More Bristol Myers Squibb News

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Zacks Research modestly raised its earnings forecasts for Bristol Myers Squibb, increasing estimates for third-quarter 2027 EPS to $1.56, full-year 2027 EPS to $6.24, first- and second-quarter 2028 EPS to $1.48 and $1.38, respectively, and full-year 2028 EPS to $5.23 from $5.17. The revisions suggest slightly improved expectations for the company’s future earnings. Zacks Research estimates
• Positive Sentiment: BMY was added to Zacks’ Rank #1 Strong Buy list and its Strong Buy income-stock list. The ratings may support demand for the shares, particularly because Bristol Myers Squibb offers significant cash flow and an attractive dividend profile. Zacks Strong Buy list
• Positive Sentiment: The company selected Onco360 as a restricted specialty-pharmacy provider for ZENBEXUS (iberdomide), its newly approved multiple-myeloma treatment. The distribution arrangement and clinical support could help the drug reach eligible patients during its commercial rollout. ZENBEXUS pharmacy network
• Positive Sentiment: Bristol Myers Squibb completed a Phase 1 lung-cancer combination study, providing incremental support for its immuno-oncology pipeline. Analysts also highlighted newer medicines as increasingly important in offsetting declines from mature products. Lung cancer study update
• Negative Sentiment: Despite the near-term positives, investors remain concerned about patent expirations and declines in established blockbuster products. Longer-term Zacks estimates remain below current-year expectations, underscoring the need for newer drugs such as ZENBEXUS to replace lost revenue.

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company that discovers, develops and commercializes prescription medicines. Its portfolio includes therapies for cancer, blood disorders, cardiovascular disease, immune-mediated conditions and psychiatric disorders. Key products include Opdivo and Yervoy for oncology, Eliquis for reducing the risk of stroke and systemic embolism, Revlimid for certain blood cancers, and several other specialty medicines.

The company serves patients and healthcare providers in markets around the world, with operations and commercial activities spanning North America, Europe, Asia-Pacific and other international regions.